Home / Business and Economy / Mankind Pharma's Q2 Profit Surges 37.7% on Strong Domestic Demand
Mankind Pharma's Q2 Profit Surges 37.7% on Strong Domestic Demand
26 Oct
Summary
- Net profit grew 37.7% year-on-year to ₹716 crore in Q2 FY27.
- Domestic revenue increased by 14.8%, driven by cardiac and anti-diabetes drugs.
- International revenue saw a 33% rise, boosted by Mankind and BSV International.
Delhi-based Mankind Pharma announced a significant financial achievement, with its consolidated net profit soaring by 37.7% year-on-year for the September quarter of FY27. The company posted a profit after tax of ₹716 crore, a notable increase from ₹520 crore in the same period last year. This impressive growth was propelled by strong domestic market performance, which constitutes 86% of its total revenue.
The drugmaker's domestic revenue expanded by 14.8% to ₹3,657 crore, primarily due to high demand for its chronic drugs treating conditions such as cardiac issues and diabetes. While the company's over-the-counter consumer healthcare business experienced muted growth of 1.2%, its international operations flourished, with revenue escalating by 33% to ₹2,061 crore. This expansion was supported by robust performance from both Mankind and Bharat Serums and Vaccines' international segments.
Further strengthening its future prospects, Mankind Pharma recently acquired Armed Cell Therapeutics, marking a strategic entry into next-generation CAR-T therapies. This move is expected to enhance its research and development capabilities. The company's stock closed positively on the BSE following the announcement of its financial results.
